Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Faeth Therapeutics, Inc. (FTH)
USD31.47
-1.65 (-4.98%)
US NASDAQ Healthcare Biotechnology
Address
1405 Research Blvd 20850
Rockville, MD, US
Rockville, MD, US
CEO
Anand Parikh
Website
faeththerapeutics.com
IPO
2014-08-11
CIK 1829802 ISIN US81728A2078
Also trades on
NASDAQ Capital Market · FTH (USD)
NASDAQ Global Market · SNSE (USD)
Description
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD31.47
-1.65 (-4.98%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
57.3K
Beta
-0.26
Float Shares
246.5K
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.03% | +62.00% | +6.26% | -41.67% | +101.13% | +67.01% | +132.64% | -34.00% | -91.99% | -95.29% | -95.29% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Buy
Price Targets & DCF
Current price
31.47
Low
50.00
+58.9%
Consensus
50.00
+58.9%
Median
50.00
+58.9%
High
50.00
+58.9%
DCF (Unlevered)
5.16
-83.6%
DCF (Levered)
5.68
-82.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 5 | +1 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
50.00
+58.9%
|
| Last Quarter | 1 |
50.00
+58.9%
|
| Last Year | 1 |
50.00
+58.9%
|
| All Time | 3 |
20.33
-35.4%
|
Quality scores
Altman Z-Score
-4.14
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-1,293.3% Q1'26: -48,585.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +6,445.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-95.0% ★ Q1'26: -94.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.07× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2025 actual |
Dec 2026 4 EPS Ana. |
Dec 2027 4 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|
| Revenue |
—
|
—
— – —
|
—
— – —
|
16.83M
16.83M – 16.83M
|
| EBITDA |
-20.91M
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-21.05M
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-21.09M
est: -183.17M (+88.5%)
|
-114.16M
-203.00M – -25.32M
+37.7% YoY
|
-11.24M
-17.47M – -5.01M
+90.2% YoY
|
-8.00M
-12.24M – -3.75M
+28.9% YoY
|
| SGA |
11.33M
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-16.72
est: -145.28 (+88.5%)
|
-104.31
-161.01 – -20.08
+28.2% YoY
|
-7.90
-13.86 – -3.97
+92.4% YoY
|
-5.38
-9.71 – -2.97
+31.8% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-06-15 | BTIG | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-18 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-06-17 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-06-16 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-06-15 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-06-12 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-06-11 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-06-10 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-06-09 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-06-08 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-06-05 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-06-04 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-06-03 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-06-02 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-06-01 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-28 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-27 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-26 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-22 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-12 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
9
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 115.4K | 0.60% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.85
Neutral
Ratio by volume
3.00
Bullish
Buys
17
Sells
20
Shares acquired
1.21M
Shares disposed
69.0K
Cash buys
8.00
Cash sales
18.00
Net activity
+1,145,649
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-15 | Parikh Anand Kiran | Director / Officer | C-Conversion | A | Common Stock | 761,428 | 0.00 | — | 761,428 | D | ↗ |
| 2026-06-15 | Hahn Stephen M. | Director | C-Conversion | A | Common Stock | 44,763 | 0.00 | — | 44,763 | D | ↗ |
| 2026-06-12 | Ramasastry Saira | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 13.00 | 325.0K | 25,000 | D | ↗ |
| 2026-06-12 | Hahn Stephen M. | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 13.00 | 325.0K | 25,000 | D | ↗ |
| 2026-06-10 | Holmen Bob | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 11.41 | 142.6K | 12,500 | D | ↗ |
| 2026-06-10 | Gerry Christopher | Officer | A-Award | A | Stock Option (right to buy) | 220,000 | 29.89 | 6.58M | 220,000 | D | ↗ |
| 2026-06-10 | Donenberg Phillip B. | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 11.41 | 142.6K | 12,500 | D | ↗ |
| 2026-06-01 | Peyer James | 10% Owner | S-Sale | D | Common Stock | 24,524 | 20.00 | 490.5K | 130,618 | D | ↗ |
| 2026-06-01 | Cambrian BioPharma Inc | 10% Owner | S-Sale | D | Common Stock | 24,524 | 20.00 | 490.5K | 130,618 | D | ↗ |
| 2026-04-10 | Donenberg Phillip B. | Director | A-Award | A | Stock Option (right to buy) | 23,100 | 29.89 | 690.5K | 23,100 | D | ↗ |
| 2026-04-10 | Craver Josiah | Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 29.89 | 2.39M | 80,000 | D | ↗ |
| 2026-04-07 | MILLENNIUM MANAGEMENT LLC | 10% Owner | S-Sale | D | Common Stock | 1,108 | 33.38 | 37.0K | 133,986 | I | ↗ |
| 2026-04-06 | MILLENNIUM MANAGEMENT LLC | 10% Owner | P-Purchase | A | Common Stock | 1,104 | 31.02 | 34.2K | 141,029 | I | ↗ |
| 2026-04-02 | MILLENNIUM MANAGEMENT LLC | 10% Owner | S-Sale | D | Common Stock | 3,099 | 30.86 | 95.6K | 144,974 | I | ↗ |
| 2026-04-01 | MILLENNIUM MANAGEMENT LLC | 10% Owner | P-Purchase | A | Common Stock | 3,401 | 35.46 | 120.6K | 147,731 | I | ↗ |
| 2026-03-31 | MILLENNIUM MANAGEMENT LLC | 10% Owner | P-Purchase | A | Common Stock | 186 | 30.48 | 5.7K | 146,657 | I | ↗ |
| 2026-03-30 | MILLENNIUM MANAGEMENT LLC | 10% Owner | S-Sale | D | Common Stock | 370 | 27.68 | 10.2K | 145,678 | I | ↗ |
| 2026-03-27 | MILLENNIUM MANAGEMENT LLC | 10% Owner | P-Purchase | A | Common Stock | 294 | 28.13 | 8.3K | 142,360 | I | ↗ |
| 2026-03-26 | MILLENNIUM MANAGEMENT LLC | 10% Owner | P-Purchase | A | Common Stock | 778 | 27.23 | 21.2K | 131,370 | I | ↗ |
| 2026-02-19 | Parikh Anand Kiran | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 1,239,305 | 27.22 | 33.73M | 1,239,305 | D | ↗ |
| 2026-02-17 | Parikh Anand Kiran | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 56,673 | 1.16 | 65.7K | 56,673 | D | ↗ |
| 2026-02-13 | Donenberg Phillip B. | Director | A-Award | A | Stock Option (right to buy) | 1,900 | 9.09 | 17.3K | 1,900 | D | ↗ |
| 2025-12-09 | Peyer James | 10% Owner | M-Exempt | D | Stock Option (Right to Buy) | 395 | 6.40 | 2.5K | 0 | D | ↗ |
| 2025-12-09 | Cambrian BioPharma Inc | 10% Owner | M-Exempt | D | Stock Option (Right to Buy) | 395 | 6.40 | 2.5K | 0 | D | ↗ |
| 2025-12-08 | Peyer James | 10% Owner | S-Sale | D | Common Stock | 3,105 | 8.59 | 26.7K | 158,254 | I | ↗ |
| 2025-12-05 | Peyer James | 10% Owner | S-Sale | D | Common Stock | 42 | 13.16 | 552.72 | 161,359 | I | ↗ |
| 2025-12-05 | Cambrian BioPharma Inc | 10% Owner | S-Sale | D | Common Stock | 42 | 13.16 | 552.72 | 161,359 | D | ↗ |
| 2025-12-04 | Peyer James | 10% Owner | S-Sale | D | Common Stock | 5,000 | 9.06 | 45.3K | 177,654 | I | ↗ |
| 2025-12-04 | Cambrian BioPharma Inc | 10% Owner | S-Sale | D | Common Stock | 5,000 | 9.06 | 45.3K | 177,654 | D | ↗ |
| 2025-11-14 | Gerry Christopher | Officer | — | — | Sock Option (Right to Buy) | 4,999 | 9.00 | 45.0K | 0 | D | ↗ |
| 2025-05-21 | RINGO WILLIAM R | Director | A-Award | A | Stock Option (Right to Buy) | 19,000 | 0.32 | 6.1K | 19,000 | D | ↗ |
| 2025-05-21 | RICKS THOMAS G | Director | A-Award | A | Stock Option (Right to Buy) | 19,000 | 0.32 | 6.1K | 19,000 | D | ↗ |
| 2025-05-21 | Peyer James | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 19,000 | 0.32 | 6.1K | 19,000 | I | ↗ |
| 2025-05-21 | Humer Kristian | Director | A-Award | A | Stock Option (Right to Buy) | 19,000 | 0.32 | 6.1K | 19,000 | D | ↗ |
| 2025-05-21 | Holmen Bob | Director | A-Award | A | Stock Option (Right to Buy) | 19,000 | 0.32 | 6.1K | 19,000 | D | ↗ |
| 2025-05-21 | Cambrian BioPharma Inc | 10% Owner | A-Award | A | Stock Option (Right to Buy) | 19,000 | 0.32 | 6.1K | 19,000 | D | ↗ |
| 2025-02-19 | van der Horst Edward | Officer | F-InKind | D | Common Stock | 2,276 | 0.48 | 1.1K | 59,794 | D | ↗ |
| 2025-02-19 | Celebi John | Director / Officer | F-InKind | D | Common Stock | 5,558 | 0.48 | 2.6K | 105,862 | D | ↗ |
| 2025-02-14 | van der Horst Edward | Officer | A-Award | A | Stock Option (Right to Buy) | 110,000 | 0.48 | 52.4K | 110,000 | D | ↗ |
| 2025-02-14 | Krebs Stephanie | Officer | A-Award | A | Stock Option (Right to Buy) | 120,000 | 0.48 | 57.1K | 120,000 | D | ↗ |
| 2025-02-14 | Craver Josiah | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 0.48 | 23.8K | 50,000 | D | ↗ |
| 2025-02-14 | Celebi John | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 360,000 | 0.48 | 171.4K | 360,000 | D | ↗ |
| 2024-12-20 | van der Horst Edward | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.45 | 45.0K | 100,000 | D | ↗ |
| 2024-12-20 | Krebs Stephanie | Officer | A-Award | A | Stock Option (Right to Buy) | 120,000 | 0.45 | 54.0K | 120,000 | D | ↗ |
| 2024-12-20 | Craver Josiah | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.45 | 45.0K | 100,000 | D | ↗ |
| 2024-12-20 | Celebi John | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 355,000 | 0.45 | 159.7K | 355,000 | D | ↗ |
| 2024-09-17 | Craver Josiah | Officer | — | — | Stock Option (Right to Buy) | 80,000 | 0.66 | 52.8K | 0 | D | ↗ |
| 2024-06-11 | Vojta Deneen | Director | A-Award | A | Stock Option (Right to Buy) | 19,000 | 0.71 | 13.5K | 19,000 | — | ↗ |
| 2024-06-11 | RINGO WILLIAM R | Director | A-Award | A | Stock Option (Right to Buy) | 19,000 | 0.71 | 13.5K | 19,000 | — | ↗ |
| 2024-06-11 | RICKS THOMAS G | Director | A-Award | A | Stock Option (Right to Buy) | 19,000 | 0.71 | 13.5K | 19,000 | — | ↗ |
| 2024-06-11 | Peyer James | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 19,000 | 0.71 | 13.5K | 19,000 | — | ↗ |
| 2024-06-11 | Humer Kristian | Director | A-Award | A | Stock Option (Right to Buy) | 19,000 | 0.71 | 13.5K | 19,000 | — | ↗ |
| 2024-06-11 | Holmen Bob | Director | A-Award | A | Stock Option (Right to Buy) | 19,000 | 0.71 | 13.5K | 19,000 | — | ↗ |
| 2024-06-11 | English Jessie | Director | A-Award | A | Stock Option (Right to Buy) | 19,000 | 0.71 | 13.5K | 19,000 | — | ↗ |
| 2024-06-11 | Cambrian BioPharma Inc | 10% Owner | A-Award | A | Stock Option (Right to Buy) | 19,000 | 0.71 | 13.5K | 19,000 | — | ↗ |
| 2024-05-10 | Gaiero David G | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-15 | van der Horst Edward | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 0.79 | 98.8K | 125,000 | — | ↗ |
| 2024-02-15 | Colgan Erin | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 0.79 | 98.8K | 125,000 | — | ↗ |
| 2024-02-15 | Celebi John | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 315,000 | 0.79 | 248.9K | 315,000 | — | ↗ |
| 2023-11-01 | Krebs Stephanie | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-09-11 | Celebi John | Director / Officer | P-Purchase | A | Common Stock | 500 | 0.85 | 425.00 | 111,311 | — | ↗ |
| 2023-07-31 | Peyer James | Director / 10% Owner | D-Return | D | Common Stock | 1,587,302 | 1.26 | 2.00M | 3,653,120 | — | ↗ |
| 2023-07-31 | Cambrian BioPharma Inc | 10% Owner | D-Return | D | Common Stock | 1,587,302 | 1.26 | 2.00M | 3,653,120 | — | ↗ |
| 2023-07-10 | Vojta Deneen | Director | A-Award | A | Common Stock | 4,466 | 0.00 | — | 8,932 | — | ↗ |
| 2023-07-10 | RINGO WILLIAM R | Director | A-Award | A | Stock Option (Right to Buy) | 14,550 | 1.22 | 17.8K | 14,550 | — | ↗ |
| 2023-07-10 | RICKS THOMAS G | Director | A-Award | A | Common Stock | 4,466 | 0.00 | — | 8,932 | — | ↗ |
| 2023-07-10 | Peyer James | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 14,550 | 1.22 | 17.8K | 14,550 | — | ↗ |
| 2023-07-10 | Humer Kristian | Director | A-Award | A | Common Stock | 4,466 | 0.00 | — | 8,932 | — | ↗ |
| 2023-07-10 | Holmen Bob | Director | A-Award | A | Stock Option (Right to Buy) | 14,550 | 1.22 | 17.8K | 14,550 | — | ↗ |
| 2023-07-10 | English Jessie | Director | A-Award | A | Common Stock | 4,466 | 0.00 | — | 8,932 | — | ↗ |
| 2023-07-10 | Cambrian BioPharma Inc | 10% Owner | A-Award | A | Stock Option (Right to Buy) | 14,550 | 1.22 | 17.8K | 14,550 | — | ↗ |
| 2023-07-10 | Broder Samuel | Director | A-Award | A | Stock Option (Right to Buy) | 14,550 | 1.22 | 17.8K | 14,550 | — | ↗ |
| 2023-06-01 | Apeiron Investment Group Ltd. | 10% Owner | S-Sale | D | Common Stock | 955,738 | 1.58 | 1.51M | 0 | — | ↗ |
| 2023-02-23 | Apeiron Investment Group Ltd. | 10% Owner | P-Purchase | A | Common Stock | 1,100 | 1.60 | 1.8K | 2,485,923 | — | ↗ |
| 2023-02-15 | van der Horst Edward | Officer | F-InKind | D | Common Stock | 9,525 | 1.50 | 14.3K | 52,913 | — | ↗ |
| 2023-02-15 | Gallagher Patrick Stephen | Officer | F-InKind | D | Common Stock | 9,383 | 1.50 | 14.1K | 34,130 | — | ↗ |
| 2023-02-15 | Colgan Erin | Officer | F-InKind | D | Common Stock | 10,943 | 1.50 | 16.4K | 68,089 | — | ↗ |
| 2023-02-15 | Celebi John | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 90,000 | 1.43 | 128.7K | 90,000 | — | ↗ |
| 2022-12-07 | van der Horst Edward | Officer | — | D | Stock Option (Right to Buy) | 44,000 | 4.30 | 189.2K | — | — | ↗ |
| 2022-07-14 | Apeiron Investment Group Ltd. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 2,483,723 | — | ↗ |
| 2022-06-10 | Vojta Deneen | Director | A-Award | A | Stock Option (Right to Buy) | 14,550 | 0.00 | — | 14,550 | — | ↗ |
| 2022-06-10 | RICKS THOMAS G | Director | A-Award | A | Common Stock | 4,466 | 0.00 | — | 4,466 | — | ↗ |
| 2022-06-10 | Peyer James | Director | A-Award | A | Stock Option (right to buy) | 14,550 | 0.00 | — | 14,550 | — | ↗ |
| 2022-06-10 | Humer Kristian | Director | A-Award | A | Common Stock | 4,466 | 0.00 | — | 4,466 | — | ↗ |
| 2022-06-10 | Holmen Bob | Director | A-Award | A | Common Stock | 4,466 | 0.00 | — | 21,132 | — | ↗ |
| 2022-06-10 | English Jessie | Director | A-Award | A | Common Stock | 4,466 | 0.00 | — | 4,466 | — | ↗ |
| 2022-06-10 | Cambrian BioPharma Inc | 10% Owner | A-Award | A | Stock Option (right to buy) | 14,550 | 2.05 | 29.8K | 14,550 | — | ↗ |
| 2022-06-10 | Broder Samuel | Director | A-Award | A | Common Stock | 4,466 | 0.00 | — | 4,466 | — | ↗ |
| 2022-06-01 | Gallagher Patrick Stephen | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 0.00 | — | 150,000 | — | ↗ |
| 2022-03-08 | RINGO WILLIAM R | Director | A-Award | A | Stock Option (Right to Buy) | 29,100 | 3.08 | 89.6K | 29,100 | — | ↗ |
| 2022-03-02 | Peyer James | Director | P-Purchase | A | Common Stock | 1,203 | 3.20 | 3.8K | 5,231,989 | — | ↗ |
| 2022-03-02 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 1,203 | 3.20 | 3.8K | 5,231,488 | — | ↗ |
| 2022-03-01 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 2,458 | 3.60 | 8.8K | 5,230,786 | — | ↗ |
| 2022-03-01 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 2,458 | 3.60 | 8.8K | 5,230,786 | — | ↗ |
| 2022-02-28 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 42 | 3.60 | 151.20 | 5,228,328 | — | ↗ |
| 2022-02-28 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 42 | 3.60 | 151.20 | 5,228,328 | — | ↗ |
| 2022-02-25 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 2,500 | 3.65 | 9.1K | 5,228,286 | — | ↗ |
| 2022-02-25 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 2,500 | 3.65 | 9.1K | 5,228,286 | — | ↗ |
| 2022-02-24 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 15,000 | 3.63 | 54.5K | 5,225,786 | — | ↗ |
| 2022-02-24 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 15,000 | 3.63 | 54.5K | 5,225,786 | — | ↗ |
| 2022-02-23 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 2,500 | 3.80 | 9.5K | 5,210,786 | — | ↗ |
| 2022-02-23 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 2,500 | 3.80 | 9.5K | 5,210,786 | — | ↗ |
| 2022-02-18 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 15,000 | 3.97 | 59.6K | 5,208,286 | — | ↗ |
| 2022-02-18 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 15,000 | 3.97 | 59.6K | 5,208,286 | — | ↗ |
| 2022-02-17 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 4,949 | 4.17 | 20.6K | 5,193,286 | — | ↗ |
| 2022-02-17 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 4,949 | 4.17 | 20.6K | 5,193,286 | — | ↗ |
| 2022-02-16 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 2,551 | 4.25 | 10.8K | 5,188,337 | — | ↗ |
| 2022-02-16 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 2,551 | 4.25 | 10.8K | 5,188,337 | — | ↗ |
| 2022-02-15 | Pierce Robert Hamilton | Officer | A-Award | A | Stock Option (Right to Buy) | 62,000 | 4.30 | 266.6K | 62,000 | — | ↗ |
| 2022-02-15 | Colgan Erin | Officer | A-Award | A | Stock Option (Right to Buy) | 62,000 | 4.30 | 266.6K | 62,000 | — | ↗ |
| 2022-02-15 | Celebi John | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 161,600 | 4.30 | 694.9K | 161,600 | — | ↗ |
| 2022-02-14 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 10,000 | 4.18 | 41.8K | 5,185,786 | — | ↗ |
| 2022-02-14 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 10,000 | 4.18 | 41.8K | 5,185,786 | — | ↗ |
| 2022-02-11 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 12,500 | 4.40 | 55.0K | 5,175,786 | — | ↗ |
| 2022-02-11 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 12,500 | 4.40 | 55.0K | 5,175,786 | — | ↗ |
| 2022-02-10 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 5,000 | 4.58 | 22.9K | 5,163,286 | — | ↗ |
| 2022-02-10 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 5,000 | 4.58 | 22.9K | 5,163,286 | — | ↗ |
| 2022-02-08 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 10,000 | 4.33 | 43.3K | 5,158,286 | — | ↗ |
| 2022-02-08 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 10,000 | 4.33 | 43.3K | 5,158,286 | — | ↗ |
| 2022-02-04 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 2,500 | 4.45 | 11.1K | 5,148,286 | — | ↗ |
| 2022-02-04 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 2,500 | 4.45 | 11.1K | 5,148,286 | — | ↗ |
| 2022-02-03 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 17,500 | 4.65 | 81.4K | 5,145,786 | — | ↗ |
| 2022-02-03 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 17,500 | 4.65 | 81.4K | 5,145,786 | — | ↗ |
| 2022-01-28 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 8,900 | 4.22 | 37.6K | 5,128,286 | — | ↗ |
| 2022-01-28 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 8,900 | 4.22 | 37.6K | 5,128,286 | — | ↗ |
| 2022-01-27 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 6,100 | 4.31 | 26.3K | 5,119,386 | — | ↗ |
| 2022-01-27 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 6,100 | 4.31 | 26.3K | 5,119,386 | — | ↗ |
| 2022-01-26 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 29,900 | 4.62 | 138.1K | 5,113,286 | — | ↗ |
| 2022-01-26 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 29,900 | 4.62 | 138.1K | 5,113,286 | — | ↗ |
| 2022-01-25 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 20,100 | 4.86 | 97.7K | 5,083,386 | — | ↗ |
| 2022-01-25 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 20,100 | 4.86 | 97.7K | 5,083,386 | — | ↗ |
| 2022-01-24 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 22,707 | 4.69 | 106.5K | 5,063,286 | — | ↗ |
| 2022-01-24 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 22,707 | 4.69 | 106.5K | 5,063,286 | — | ↗ |
| 2022-01-21 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 24,703 | 4.94 | 122.0K | 5,040,579 | — | ↗ |
| 2022-01-21 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 24,703 | 4.94 | 122.0K | 5,040,579 | — | ↗ |
| 2022-01-20 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 20,000 | 5.17 | 103.4K | 5,015,876 | — | ↗ |
| 2022-01-20 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 20,000 | 5.17 | 103.4K | 5,015,876 | — | ↗ |
| 2022-01-19 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 10,244 | 4.97 | 50.9K | 4,995,876 | — | ↗ |
| 2022-01-19 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 10,244 | 4.97 | 50.9K | 4,995,876 | — | ↗ |
| 2022-01-18 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 10,000 | 5.08 | 50.8K | 4,985,632 | — | ↗ |
| 2022-01-18 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 10,000 | 5.08 | 50.8K | 4,985,632 | — | ↗ |
| 2022-01-14 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 6,219 | 4.99 | 31.0K | 4,975,632 | — | ↗ |
| 2022-01-14 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 6,219 | 4.99 | 31.0K | 4,975,632 | — | ↗ |
| 2022-01-13 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 19,953 | 5.13 | 102.4K | 4,969,413 | — | ↗ |
| 2022-01-13 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 19,953 | 5.13 | 102.4K | 4,969,413 | — | ↗ |
| 2022-01-12 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 9,202 | 5.22 | 48.0K | 4,949,460 | — | ↗ |
| 2022-01-12 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 9,202 | 5.22 | 48.0K | 4,949,460 | — | ↗ |
| 2022-01-11 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 10,845 | 5.18 | 56.2K | 4,940,258 | — | ↗ |
| 2022-01-11 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 10,845 | 5.18 | 56.2K | 4,940,258 | — | ↗ |
| 2022-01-10 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 10,000 | 5.28 | 52.8K | 4,929,413 | — | ↗ |
| 2022-01-10 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 10,000 | 5.28 | 52.8K | 4,929,413 | — | ↗ |
| 2021-12-30 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 1,127 | 4.85 | 5.5K | 4,919,413 | — | ↗ |
| 2021-12-30 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 1,127 | 4.85 | 5.5K | 4,919,413 | — | ↗ |
| 2021-12-29 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 69,000 | 4.98 | 343.6K | 4,918,286 | — | ↗ |
| 2021-12-29 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 69,000 | 4.98 | 343.6K | 4,918,286 | — | ↗ |
| 2021-12-28 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 11,288 | 5.28 | 59.6K | 4,849,286 | — | ↗ |
| 2021-12-28 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 11,288 | 5.28 | 59.6K | 4,849,286 | — | ↗ |
| 2021-12-27 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 3,712 | 5.30 | 19.7K | 4,837,998 | — | ↗ |
| 2021-12-27 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 3,712 | 5.30 | 19.7K | 4,837,998 | — | ↗ |
| 2021-12-23 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 11,000 | 5.27 | 58.0K | 4,834,286 | — | ↗ |
| 2021-12-23 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 11,000 | 5.27 | 58.0K | 4,834,286 | — | ↗ |
| 2021-12-17 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 117 | 5.29 | 618.93 | 4,823,286 | — | ↗ |
| 2021-12-17 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 117 | 5.29 | 618.93 | 4,823,286 | — | ↗ |
| 2021-12-16 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 10,925 | 5.25 | 57.4K | 4,823,169 | — | ↗ |
| 2021-12-16 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 10,925 | 5.25 | 57.4K | 4,823,169 | — | ↗ |
| 2021-12-10 | RICKS THOMAS G | Director | P-Purchase | A | Common Stock | 20,000 | 5.86 | 117.2K | 341,769 | — | ↗ |
| 2021-12-09 | RICKS THOMAS G | Director | P-Purchase | A | Common Stock | 20,000 | 6.62 | 132.4K | 321,769 | — | ↗ |
| 2021-08-11 | Pierce Robert Hamilton | Officer | S-Sale | D | Common Stock | 16,030 | 7.34 | 117.7K | 0 | — | ↗ |
| 2021-08-10 | Pierce Robert Hamilton | Officer | S-Sale | D | Common Stock | 66,350 | 7.13 | 473.0K | 16,030 | — | ↗ |
| 2021-08-09 | Pierce Robert Hamilton | Officer | S-Sale | D | Common Stock | 6,982 | 7.06 | 49.3K | 82,380 | — | ↗ |
| 2021-08-06 | Pierce Robert Hamilton | Officer | S-Sale | D | Common Stock | 6,460 | 7.11 | 45.9K | 89,362 | — | ↗ |
| 2021-07-30 | Humer Kristian | Director | A-Award | A | Stock Option (Right to Buy) | 16,667 | 7.89 | 131.5K | 16,667 | — | ↗ |
| 2021-05-05 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 350 | 12.00 | 4.2K | 4,812,244 | — | ↗ |
| 2021-05-05 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 350 | 12.00 | 4.2K | 4,812,244 | — | ↗ |
| 2021-04-20 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 385 | 12.77 | 4.9K | 4,811,894 | — | ↗ |
| 2021-04-20 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 385 | 12.77 | 4.9K | 4,811,894 | — | ↗ |
| 2021-04-19 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 1,965 | 13.38 | 26.3K | 4,811,509 | — | ↗ |
| 2021-04-19 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 1,965 | 13.38 | 26.3K | 4,811,509 | — | ↗ |
| 2021-04-13 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 2,000 | 14.00 | 28.0K | 4,809,544 | — | ↗ |
| 2021-04-13 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 2,000 | 14.00 | 28.0K | 4,809,544 | — | ↗ |
| 2021-04-07 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 2,000 | 14.00 | 28.0K | 4,807,544 | — | ↗ |
| 2021-04-07 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 2,000 | 14.00 | 28.0K | 4,807,544 | — | ↗ |
| 2021-04-01 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 1,000 | 14.00 | 14.0K | 4,805,544 | — | ↗ |
| 2021-04-01 | English Jessie | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-04-01 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 1,000 | 14.00 | 14.0K | 4,805,544 | — | ↗ |
| 2021-03-30 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 2,000 | 12.00 | 24.0K | 4,804,544 | — | ↗ |
| 2021-03-30 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 2,000 | 12.00 | 24.0K | 4,804,544 | — | ↗ |
| 2021-03-24 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 3,750 | 14.12 | 53.0K | 4,802,544 | — | ↗ |
| 2021-03-24 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 3,750 | 14.12 | 53.0K | 4,802,544 | — | ↗ |
| 2021-03-23 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 10,000 | 14.34 | 143.4K | 4,798,794 | — | ↗ |
| 2021-03-23 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 9,500 | 14.34 | 136.2K | 4,798,293 | — | ↗ |
| 2021-03-22 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 2,183 | 15.02 | 32.8K | 4,788,794 | — | ↗ |
| 2021-03-22 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 2,183 | 15.02 | 32.8K | 4,788,794 | — | ↗ |
| 2021-03-18 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 817 | 15.25 | 12.5K | 4,786,611 | — | ↗ |
| 2021-03-18 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 817 | 15.25 | 12.5K | 4,786,611 | — | ↗ |
| 2021-03-08 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 1,000 | 15.25 | 15.2K | 4,785,794 | — | ↗ |
| 2021-03-08 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 1,000 | 15.25 | 15.2K | 4,785,794 | — | ↗ |
| 2021-03-05 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 8,000 | 13.75 | 110.0K | 4,784,794 | — | ↗ |
| 2021-03-05 | Cambrian BioPharma Inc | 10% Owner | P-Purchase | A | Common Stock | 8,000 | 13.75 | 110.0K | 4,784,794 | — | ↗ |
| 2021-03-04 | Peyer James | Director / 10% Owner | P-Purchase | A | Common Stock | 2,000 | 14.13 | 28.3K | 4,776,794 | — | ↗ |
Executive team
Top executives
Shares Outstanding
1.34M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | John Celebi Former President and Chief Executive Officer | 481.9K | — | — | 133.6K | — | 645.0K | 1.26M | 10.60% | ↗ |
| 2 | 2025 | Edward van der Horst, Ph.D. Former Chief Scientific Officer | 357.1K | — | — | 40.8K | — | 351.3K | 749.2K | 5.45% | ↗ |
| 3 | 2025 | Stephanie Krebs Former Chief Business Officer | 346.4K | — | — | 44.5K | — | 339.7K | 730.7K | 6.09% | ↗ |
| 4 | 2025 | Christopher W. Gerry President and General Counsel | 398.2K | — | — | 18.6K | — | 17.9K | 434.6K | 4.27% | ↗ |
| 5 | 2025 | Josiah Craver SVP, Finance | 372.7K | — | — | 18.6K | — | 18.5K | 409.7K | 4.53% | ↗ |
| 6 | 2024 | John Celebi President and Chief Executive Officer | 535.6K | — | — | 311.3K | 268.8K | 68.0K | 1.18M | 26.30% | ↗ |
| 7 | 2024 | John Celebi Former President and Chief Executive Officer | 535.6K | — | — | 311.3K | 268.8K | 68.0K | 1.18M | 26.30% | ↗ |
| 8 | 2024 | Edward van der Horst, Ph.D. Chief Scientific Officer | 400.0K | — | — | 109.9K | 142.0K | 15.8K | 667.7K | 16.47% | ↗ |
| 9 | 2024 | Edward van der Horst, Ph.D. Former Chief Scientific Officer | 400.0K | — | — | 109.9K | 142.0K | 15.8K | 667.7K | 16.47% | ↗ |
| 10 | 2024 | Stephanie Krebs Former Chief Business Officer | 385.0K | — | — | 40.6K | 140.5K | 18.3K | 584.4K | 6.95% | ↗ |
| 11 | 2024 | Stephanie Krebs Chief Business Officer | 385.0K | — | — | 40.6K | 140.5K | 18.3K | 584.4K | 6.95% | ↗ |
| 12 | 2023 | John Celebi President and Chief Executive Officer | 532.2K | — | 30.5K | 99.6K | 285.7K | 64.4K | 1.01M | 12.84% | ↗ |
| 13 | 2023 | Edward van der Horst, Ph.D. Chief Scientific Officer | 382.7K | — | 25.3K | 83.0K | 230.2K | 17.9K | 739.1K | 14.65% | ↗ |
| 14 | 2023 | Erin Colgan Former Chief Financial Officer | 423.7K | — | 30.5K | 99.6K | 162.1K | 18.4K | 734.2K | 17.71% | ↗ |
| 15 | 2022 | John Celebi President and Chief Executive Officer | 512.5K | — | 231.8K | 537.4K | 228.0K | 59.2K | 1.57M | 49.03% | ↗ |
| 16 | 2022 | Robert Pierce, M.D. Former Chief R&D Officer | 421.2K | — | 90.3K | 298.3K | — | 377.6K | 1.19M | 32.73% | ↗ |
| 17 | 2022 | Erin Colgan Former Chief Financial Officer | 410.0K | — | 90.3K | 206.2K | 132.0K | 16.8K | 855.3K | 34.66% | ↗ |
| 18 | 2022 | Erin Colgan Chief Financial Officer | 410.0K | — | 90.3K | 206.2K | 132.0K | 16.8K | 855.3K | 34.66% | ↗ |
| 19 | 2022 | Edward van der Horst, Ph.D. Chief Scientific Officer | 326.9K | — | 63.2K | 146.3K | 103.5K | 14.4K | 654.4K | 32.02% | ↗ |
| 20 | 2021 | John Celebi President and Chief Executive Officer | 487.1K | — | — | 6.12M | 264.0K | 41.9K | 6.91M | 88.52% | ↗ |
| 21 | 2021 | John Celebi Chief Executive Officer | 487.1K | — | — | 6.12M | 264.0K | 41.9K | 6.91M | 88.52% | ↗ |
| 22 | 2021 | Robert Pierce, M.D. Former Chief R&D Officer | 410.0K | — | — | 1.62M | 167.7K | 62.8K | 2.26M | 71.68% | ↗ |
| 23 | 2021 | Robert Pierce Chief Research and Development Officer | 410.0K | — | — | 1.62M | 167.7K | 62.8K | 2.26M | 71.68% | ↗ |
| 24 | 2021 | Marie-Louise Fjaellskog Former Chief Medical Officer | 345.5K | — | — | 1.16M | — | 152.0K | 1.66M | 70.02% | ↗ |
| 25 | 2021 | Anupama Hoey Former Chief Business Officer | 135.4K | — | — | 1.22M | — | 190.4K | 1.55M | 78.97% | ↗ |
| 26 | 2021 | Erin Colgan Chief Financial Officer | 317.8K | — | — | 764.6K | 123.6K | 11.8K | 1.22M | 62.79% | ↗ |
| 27 | 2020 | John Celebi Chief Executive Officer | 394.6K | — | — | 1.78M | 119.0K | 19.0K | 2.31M | 76.92% | ↗ |
| 28 | 2020 | Anupama Hoey Former Chief Business Officer | 74.5K | 25.0K | — | 1.25M | 22.1K | — | 1.37M | 91.13% | ↗ |
| 29 | 2020 | Robert Pierce Chief Research and Development Officer | 266.8K | — | — | 670.0K | 102.0K | 32.8K | 1.07M | 62.52% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christopher Gerry | President, General Counsel, Secretary & Director | 416.0K | male |
| Josiah Craver | Senior Vice President of Finance, Principal Financial Officer & Principal Accounting Officer | 391.2K | male |
| Anand Parikh | COO & Director | — | male |
| Lora Pike | Vice President of Investor Relations & Communications | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FTH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
